- Report
- January 2023
- 111 Pages
Asia Pacific
From €3280EUR$3,450USD£2,755GBP
- Report
- October 2022
- 159 Pages
Global
From €4230EUR$4,450USD£3,554GBP
- Report
- January 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- October 2023
- 145 Pages
Global
From €2995EUR$3,150USD£2,516GBP
- Report
- December 2023
- 250 Pages
Global
€4749EUR$4,995USD£3,989GBP
- Report
- May 2022
- 140 Pages
Global
From €3422EUR$3,600USD£2,875GBP
- Report
- October 2021
- 200 Pages
Global
From €3803EUR$4,000USD£3,195GBP
- Report
- October 2021
- 101 Pages
Global
From €3803EUR$4,000USD£3,195GBP
- Report
- January 2022
Global
From €7130EUR$7,500USD£5,990GBP
- Report
- January 2025
- 81 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- August 2024
- 95 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- January 2024
- 81 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- August 2022
- 78 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- May 2024
- 275 Pages
Global
From €3394EUR$3,570USD£2,851GBP
- Report
- April 2022
- 220 Pages
Global
From €3285EUR$3,456USD£2,760GBP
- Book
- January 2010
- 200 Pages

Within the field of cardiovascular devices, Left Ventricular Assist Devices (LVADs) comprise a specialized segment aimed at supporting patients with advanced heart failure. LVADs are mechanical pumps that are implanted to assist the failing left ventricle, the main pumping chamber of the heart, by maintaining adequate blood flow throughout the body. The utility of LVADs extends from serving as a bridge to heart transplantation, to being a destination therapy for patients who are not candidates for a transplant. As technology has advanced, LVADs have become more compact and reliable, leading to improvements in patient outcomes and quality of life. The market for LVADs is influenced by several factors, including technological advancements, an aging population, and the prevalence of heart failure. Collaboration between medical device manufacturers and the healthcare community is essential in driving innovation and addressing the needs of the patient population.
Some key players in the LVAD market include Abbott Laboratories, which offers the HeartMate product line, Medtronic, known for its HeartWare HVAD system, and Berlin Heart, which provides the INCOR and EXCOR devices. Other companies active in this space are Abiomed, which has developed the Impella heart pump, and Jarvik Heart, maker of the Jarvik 2000 LVAD. Show Less Read more